Obstacles and pitfalls in the PEGylation of therapeutic proteins

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 2, 2008, Pages 242-250

  Gaberc Porekar, Vladka ^a   Zore, Irena ^b   Podobnik, Barbara ^b   Menart, Viktor ^a,b  

^a NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

^b Lek Dd a Sandoz Company   (Slovenia)

Author keywords

Analysis; Auto oxidation; Biological activity; Immunogenicity; PEG; PEG polydispersity; PEGylation; PK PD profile; Protein therapeutics; Separation; Site specific PEGylation

Indexed keywords

ASPARAGINASE MACROGOL; CELASYS; MACROGOL; MACUVERSE; PEGADEMASE; PEGAPTANIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; POLYSORBATE; PROTEIN DERIVATIVE; REAGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ACCURACY; ANION EXCHANGE CHROMATOGRAPHY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; GEL PERMEATION CHROMATOGRAPHY; IMMUNOGENICITY; ION EXCHANGE CHROMATOGRAPHY; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN MODIFICATION; PROTEIN PURIFICATION; REACTION ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; SEPARATION TECHNIQUE; TECHNOLOGY;

ANIMALS; HUMANS; INDICATORS AND REAGENTS; POLYETHYLENE GLYCOLS; PROTEINS; TISSUE DISTRIBUTION;

EID: 39549112760     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Szymkowski DE: Creating the next generation of protein therapeutics through rational drug design. Curr Opin Drug Discovery Dev (2005) 8(5):590-600. •• Provides an excellent overview of various approaches toward creating the next generation of biopharmaceuticals with optimized drug properties and novel functions.
2. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP: Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov (2006) 5(2):123-132.
3. Pasut G, Veronese FM: Polymer-drug conjugation, recent achievements and general strategies. Prog Polym Sci (2007) 32(8-9):933-961.
4. Celares GmbH, Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany. www.celares.com/Produkte/produkte.php?lang=en
5. Berna M, Dalzoppo D, Pasut G, Manunta M, Izzo L, Jones AT, Duncan R, Veronese FM: Novel monodisperse PEG-dendrons as new tools for targeted drug delivery: Synthesis, characterization and cellular uptake. Biomacromolecules (2006) 7(1):146-153.
6. Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J et al: Structure-function engineering of interferon-β-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem (2006) 17(3):618-630.
7. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A et al: Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon-α-2a for the treatment of hepatitis C. Bioconjug Chem (2001) 12(2):195-202.
8. Kawai F: Microbial degradation of polyethers. Appl Microbiol Biotechnol (2002) 58(1):30-38.
9. Mehvar R: Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J Pharm Pharmaceut Sci (2000) 3(1):125-136.
10. Beranová M, Wasserbauer R, Vancurová D, Stifter M, Ocenásková J, Mára M: Effect of cytochrome P-450 inhibition and stimulation on intensity of polyethylene degradation in microsomal fraction of mouse and rat livers. Biomaterials (1990) 11(7):521-524.
11. Yamashita M, Tani A, Kawai F: A new ether bond-splitting enzyme found in Gram-positive polyethylene glycol 6000-utilizing bacterium, Pseudonocardia sp strain K1. Appl Microbiol Biotechnol (2004) 66(2):174-179.
12. Kumar V, Kalonia DS: Removal of peroxides in polyethylene glycols by vacuum drying: Implications in the stability of biotech and pharmaceutical formulations. AAPS PharmSciTech (2006) 7(3):62.
13. Seely JE, Buckel SD, Green PD, Richey CW: Making site-specific PEGylation work. BioPharm Int (2005):1-7. •• Provides a comprehensive review of the purification and analysis of PEGylated protein pharmaceuticals.
14. Ha E, Wang W, Wang YJ: Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci (2002) 91(10):2252-2264.
15. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS: Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther (2006) 8(1):R12.
16. Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfield MS: Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum (2007) 56(3):1021-1028.
17. Judge A, McClintock K, Phelps JR, MacLachlan I: Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther (2006) 13(2):328-337.
18. Wang XY, Ishida T, Kiwada H: Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release (2007) 119(2):236-244.
19. Cheng TL, Chen BM, Chern JW, Wu MF, Roffler SR: Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug Chem (2000) 11(2):258-266.
20. Kinstler O, Molineux G, Treuheit M, Ladd D, Gegg C: Mono- N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev (2002) 54(4):477-485.
21. Shaunak S, Godwin A, Choi JW, Balan S, Pedone E, Vijayarangam D, Heidelberger S, Teo I, Zloh M, Brocchini S: Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat Chem Biol (2006) 2(6):312-313. • Describes an interesting and promising strategy for site-specific PEGylation.
22. Balan S, Choi JW, Godwin A, Teo I, Laborde CM, Heidelberger S, Zloh M, Shaunak S, Brocchini S: Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. Bioconjug Chem (2007) 18(1):61-76.
23. Deiters A, Schultz PG: In vivo incorporation of an alkyne into proteins in Escherichia coli. Bioorg Med Chem Lett (2005) 15(5):1521-1524. • Describes an interesting novel approach to site-specific PEGylation.
24. Sato H: Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev (2002) 54(4):487-504.
25. DeFrees S, Wang ZG, Xing R, Scott AE, Wang J, Zopf D, Gouty DL, Sjoberg ER, Panneerselvam K, Brinkman-Van der Linden EC, Bayer RJ et al: GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology (2006) 16(9):833-843. • Describes a novel strategy for site-directed PEGylation using enzymes that is useful for relevant pharmaceutical proteins.
26. Fee CJ, Van Alstine JM: PEG-proteins: Reaction engineering and separation issues. Chem Eng Sci (2006) 61(3):924-939. •• Provides a comprehensive review of PEGylation reactions from the engineering point of view with analysis of useful separation techniques.
27. Edwards CK III, Martin SW, Seely J, Kinstler O, Buckel S, Bendele AM, Ellen Cosenza M, Feige U, Kohno T: Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv Drug Deliv Rev (2003) 55(10):1315-1336.
28. Foser S, Schacher A, Weyer KA, Brugger D, Dietel E, Marti S, Schreitmuller T: Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon-α-2a (PEGASYS). Protein Expr Purif (2003) 30(1):78-87.
29. Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ: Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol (1999) 17(8):780-783. •• Presents a strategy for the valuable site-specific PEGylation of antibody fragments for therapeutic purposes.
30. Seely JE, Richey CW: Use of ion-exchange chromatography and hydrophobic interaction chromatography in the preparation and recovery of polyethylene glycol-linked proteins. J Chromatogr A (2001) 908(1-2):235-241. •• Provides an interesting review of the purification and analysis of PEGylated protein pharmaceuticals.
31. Piedmonte DM, Treuheit MJ: Formulation of Neulasta(R) (pegfilgrastim). Adv Drug Deliv Rev (2008) 60(1):50-58.
32. Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF: Structural and biological characterization of pegylated recombinant interferon-α-2b and its therapeutic implications. Adv Drug Deliv Rev (2002) 54(4):547-570.
33. Srebalus Barnes CA, Lim A: Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals. Mass Spectrom Rev (2007) 26(3):370-388.
34. Cindrić M, Cepo T, Galić N, Bukvić-Krajacić M, Tomczyk N, Vissers JP, Bindila L, Peter-Katalinić J: Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites. J Pharm Biomed Anal (2007) 44(2):388-395.
35. Caliceti P, Veronese FM: Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev (2003) 55(10):1261-1277. •• Provides an excellent review of the pharmacokinetic properties of PEG-protein conjugates and their fate in vivo.
36. Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, Gupta SK, Tendler CL: Pegylated interferon-α-2b treatment for patients with solid tumors: A phase I/II study. J Clin Oncol (2002) 20(18):3841- 3849.
37. Gregoriadis G, Jain S, Papaioannou I, Laing P: Improving the therapeutic efficacy of peptides and proteins: A role for polysialic acids. Int J Pharm (2005) 300(1-2):125-130. •• Presents a different approach to protein bioconjugation using biodegradable polysialic acid.
38. Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L: Phase I trial of 40-kD branched pegylated interferon-α-2a for patients with advanced renal cell carcinoma. J Clin Oncol (2001) 19(5):1312-1319.
39. Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins (CHMP/EWP/89249/04). Committee for Medicinal Products for Human Use, European Medicines Agency (2005). http://www.emea.europa.eu/ pdfs/general/direct/emeaar/AnnualReport2005.pdf
40. Mahmood I, Green MD: Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet (2005) 44(4):331-347. •• Provides a comprehensive review of the bioanalytical methods used and the problems encountered in the development of therapeutic proteins.
41. Technical Guide for ELISA. KPL Inc, Gaithersburg, MD, USA. http://www.kpl.com/docs/techdocs/chapters%201%20-%204.pdf and http://www.kpl.com/docs/techdocs/chapters%205%20-%2010.pdf
42. Tsai NM, Cheng TL, Roffler SR: Sensitive measurement of polyethylene glycol-modified proteins. Biotechniques (2001) 30(2):396-402.
43. Epitomics Inc, Burlingame, CA, USA. www.epitomics.com
44. Academia Sinica, Nankang, Taipei, Taiwan. www.sinica.edu.tw/main_e. shtml
45. NEKTAR THERAPEUTICS (Bosard MJ): Composition comprising two different populations of polymer-active agent conjugates. WO-2005058366 (2005).